Rebalancing Vital Hormones – Why Testosterone Replacement Matters and How to Preserve Fertility
- Brainz Magazine
- 6 days ago
- 5 min read
Dr. Chris Bachtsetzis, a renowned biomedical scientist and Lifestyle Medicine Physician, is internationally recognized for his commitment to preventive care and longevity medicine.
Testosterone is often portrayed narrowly as “the male hormone.” Yet its influence extends far beyond libido or muscle mass. It is a cornerstone of male physiology, affecting physical health, emotional wellbeing, and quality of life more broadly. For men with chronically low testosterone levels, especially those with clinically confirmed low blood testosterone and secondary hypogonadism, testosterone replacement therapy (TRT) can be transformative. But understanding when and how to use it, and how to protect fertility at the same time, is essential.
What is testosterone deficiency and secondary hypogonadism?
Male hypogonadism is a clinical condition defined by persistently low serum testosterone accompanied by symptoms such as fatigue, low libido, mood changes, reduced muscle mass and bone density, and erectile dysfunction. In secondary hypogonadism, the problem originates in the hypothalamus or pituitary gland, suppressing signals, LH and FSH, that tell the testes to produce testosterone. This differs from primary hypogonadism, where the testes themselves are dysfunctional.
Secondary hypogonadism can be caused by pituitary tumours, inflammation, obesity, chronic illness, medications, and ageing-related changes in hormone signalling.
The case for TRT: Evidence and everyday health
TRT aims to restore testosterone to the physiological range to relieve symptoms and support normal body functions. Several peer-reviewed studies and systematic reviews have shown measurable benefits across multiple domains.
1. Improved sexual function and libido
Low testosterone is strongly correlated with reduced sexual desire and performance. TRT has been shown to significantly improve sexual function, libido, and erectile performance in men with hypogonadism.
This improvement is not merely about sex, it influences self-confidence, intimate relationships, and overall life satisfaction.
2. Enhanced energy, mood, and cognitive wellbeing
Testosterone interacts with brain chemistry. Men with low testosterone often report fatigue, depression, irritability, and brain fog. Many clinical studies report mood improvements, better motivation, sharper concentration, and reduced depressive symptoms after TRT.
3. Muscle mass, bone health, and metabolism
Testosterone supports protein synthesis, muscle growth, and bone mineral density. Low levels are associated with sarcopenia, fractures, and unfavourable metabolic markers. TRT has been shown to increase lean body mass and improve metabolic variables.
4. Cardiovascular considerations
For men with secondary hypogonadism, TRT remains a standard of care. Although cardiovascular outcomes have been debated, recent cohort data suggest that when testosterone is restored within normal physiological levels, it does not increase the risk of heart attack or stroke in most men and may support vascular health.
Key point: TRT should be carefully individualised. Levels above the normal range are not the goal and can be harmful.
TRT and fertility: A crucial trade-off
One of the most important considerations in TRT is its impact on fertility.
How TRT affects spermatogenesis
By providing exogenous testosterone, the hypothalamus and pituitary reduce production of gonadotropins, LH, and FSH, via negative feedback. These pituitary hormones are essential for stimulating intratesticular testosterone production, which is 50 to 100 times higher than systemic levels and critical for sperm production.
As a result, traditional TRT can significantly suppress sperm production, often leading to oligozoospermia or azoospermia, meaning very low or zero sperm count.
For men of reproductive age, or those wishing to father children, this suppression presents a difficult trade-off.
Hormonal strategies to preserve fertility
Human chorionic gonadotropin (hCG)
hCG acts as an LH analog, stimulating the Leydig cells in the testes to produce natural testosterone and helping maintain intratesticular testosterone levels necessary for spermatogenesis.
Clinical research indicates that:
hCG monotherapy can increase testosterone and improve subjective symptoms, including libido, energy, and erectile function, in men with hypogonadal symptoms.
hCG can restore sperm production in a significant proportion of men whose spermatogenesis has been suppressed by external testosterone or other hormonal disruption.
In men specifically wishing to preserve or restore fertility, hCG is widely considered the most reliable alternative or adjunct to TRT and may be used on its own or in combination with testosterone in carefully supervised protocols.
FSH and hMG, human menopausal gonadotropin
FSH, or hMG, which contains FSH activity, stimulates the Sertoli cells in the testes, which nurture developing sperm. In some men with significant spermatogenic impairment, combining hCG with FSH preparations can further enhance sperm counts and quality.
Protocols often start with hCG to support testosterone and Leydig cell function, then add FSH or hMG to directly stimulate the sperm producing apparatus.
Selective estrogen receptor modulators (SERMs)
Agents such as clomiphene citrate can increase endogenous LH and FSH secretion by blocking estrogen feedback in the hypothalamus. These agents can be alternatives or adjuncts to hCG in fertility-preserving approaches.
Shared decision making, TRT & proper monitoring increased the quality of life
Because hormone therapy directly influences multiple physiological systems, careful monitoring is essential. Typical monitoring includes:
Regular blood tests for testosterone, LH, FSH, estradiol, hematocrit, and PSA.
Semen analyses before and during therapy for men concerned about fertility.
Assessment of symptoms, mood, libido, and quality of life.
Cardiovascular and prostate health evaluations in appropriate age groups.
A nuanced, individualised approach, ideally with a hormonal therapy specialist medical doctor, ensures that treatment goals align first with patient safety standards, followed by health priorities, reproductive plans, and long-term wellbeing.
Follow me on Facebook, Instagram, LinkedIn, and visit my website for more info!
Dr. Chris Bachtsetzis, BSc, MD, PhD, PGCert, Lifestyle Medicine & Longevity Physician
Dr. Chris Bachtsetzis is a certified Lifestyle Medicine Physician with a strong international presence. He holds dual qualifications in Medicine and Biomedical Sciences, having also a pre-medical background in Healthcare Business, Economics, and Management, combining clinical expertise with a deep understanding of human biology and healthcare management. Dr. Chris has contributed to numerous research initiatives and clinical programmes aiming at combating chronic disease through sustainable lifestyle changes. He is a sought-after speaker at global conferences and has collaborated with leading institutions in the field of preventive medicine.
References:
Corona, G., Isidori, A. M., Aversa, A., Burnett, A. L., Maggi, M., and Endocrinology of Male Sexual Dysfunction Study Group. (2018). Efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism, 103(5), 1745–1754.
Hsieh, T. C., Pastuszak, A. W., Hwang, K., Lipshultz, L. I., and Khera, M. (2018). Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. Journal of Urology, 199(1), 257–263.
Rashid, M. I., Ibrahim, M. I., and Ghazali, A. M. (2016). Treatment of the hypogonadal infertile male: A review. Arab Journal of Urology, 14(2), 112–119.
Schlegel, P. N., Hardy, M. P., Goldstein, M., and Smith, K. D. (2006). Management of male infertility due to congenital or acquired hypogonadotropic hypogonadism. Endocrine Reviews, 27(7), 702–723.
O’Shaughnessy, P. J., Mitchell, R. T., and Anderson, R. A. (2025). Effect of pubertal induction with combined gonadotropin therapy on testicular development and spermatogenesis in males with gonadotropin deficiency. Human Reproduction Open, 2025(2), hoaf026.
Layton, T. M., Brannigan, R. E., and Schlegel, P. N. (2025). Efficacy of gonadotropin therapy to induce spermatogenesis and fertility in men with pathologic gonadotropin deficiency. Journal of Clinical Endocrinology and Metabolism. Advance online publication.
National Institute for Health and Care Excellence. (2024). Testosterone replacement therapy: Evidence synthesis and economic evaluation. NCBI Bookshelf.
Corona, G., Rastrelli, G., Monami, M., Melani, C., Balzi, D., Sforza, A., Forti, G., and Maggi, M. (2014). Factors affecting spermatogenesis upon gonadotropin-replacement therapy: A meta-analytic study. Andrology, 2(6), 794–808.
Dwyer, A. A., Sykiotis, G. P., Hayes, F. J., Boepple, P. A., Lee, H., Loughlin, K. R., and Pitteloud, N. (2020). Prior androgen therapy impacts spermatogenic response to combined gonadotropin therapy in hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism, 105(4), e1581–e1592.
Chan, Y., Boehm, U., and Dwyer, A. A. (2025). Fertility outcomes in adult males with congenital hypogonadotropic hypogonadism treated with recombinant FSH and hCG. Human Reproduction. Advance online publication.
